Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2833PDF: 846HTML: 6518Untitled: 226Untitled: 189Untitled: 202Untitled: 209 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1227PDF: 756HTML: 313 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1179PDF: 751HTML: 1347Figure 1: 186Figure 2: 188 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2575PDF: 797HTML: 5211 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3578PDF: 881HTML: 6710 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1715PDF: 1161HTML: 245 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1605PDF: 806HTML: 163 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3242PDF: 1084HTML: 433 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2897PDF: 1584HTML: 233 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3878PDF: 753HTML: 1848 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2075PDF: 1517HTML: 283 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
991PDF: 984Suppl. Files: 635HTML: 123 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7425PDF: 2415HTML: 1729Table 1.: 208Table 2.: 217Table 3.: 201Table 4.: 200 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
799PDF: 418HTML: 283 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2184PDF: 1481HTML: 264 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2571PDF: 736HTML: 2296 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1374PDF: 1305HTML: 96 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1519PDF: 941HTML: 222 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1172PDF: 830HTML: 3360 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1454PDF: 1054HTML: 215 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2130PDF: 1320HTML: 3500 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1236PDF: 982HTML: 209 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
699PDF: 381Suppl. Files: 120HTML: 112







